摘要
目的研究胰腺癌组织中P170和抑凋亡基因bcl-2的表达及其临床意义。方法对81例胰腺癌标本应用免疫组化方法测定标本中凋亡抑制基因bcl-2的基因蛋白产物以及P170蛋白表达。结果胰腺癌组织中P170、bcl-2的阳性表达率分别为67.9%和72.8%。bcl-2表达与肿瘤TNM分期有关(P<0.05),与肿瘤直径、淋巴结转移、分化程度、病理类型等无关(P>0.05),而P170阳性表达仅与分化程度有关(P<0.05)。结论胰腺是原发性耐药器官,化疗可以诱发耐药的产生,bcl-2基因和P170表达是评估胰腺癌预后的重要指标。
Objective To investigate the expression of Pl70 and bcl-2 gene in patients with pancreatic carcinoma and explore its clinical value.Methods The protein expressions of P170 and bcl-2 gene were detected by immunohistochemistry in 81 parafin-embedded specimens from patients with pancreatic carcinoma.Results The positive rates of P170 and bcl-2 protein in pancreatic carcinoma were 67.9% and 72.8% respectively.Before operation the positive expression rates of P170 and bcl-2 gene in chemotherapy group were significantly higher than those in normal pancreatic tissues and non-chemotherapy group.The expression of bcl-2 was related to TNM stage,which had no relation with tumor diameter,lymph node metastasis,the extent of differentiation and type of pathology.However the expression of P170 was only related with the extent of differentiation of tumor cell.The patients＇ survival time after operation in the group of higher expression of P170 and bcl-2 was shorter than that in the group of lower expression of P170 and bcl-2.Conclusion The pancreas is an organ of primary drug resistance,and chemotherapy can induce MDR.The expression of P170 and bcl-2 is the useful indexes for evaluating prognosis in patients with pancreatic carcinoma.
出处
《河北医药》
CAS
2011年第6期805-807,共3页
Hebei Medical Journal
基金
天津市卫生局科研基金资助项目(编号:09kz31)
